Skip to Content

Sitavig (acyclovir) Disease Interactions

There are 4 disease interactions with Sitavig (acyclovir):

Major

Acyclovir (Includes Sitavig) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Acyclovir is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance. Therapy with acyclovir should be administered cautiously in patients with renal impairment. Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.

References

  1. Laskin OL, Longstreth JA, Whelton A, et al "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982): 197-201
  2. Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994): 460-3
  3. Laskin OL, Longstreth JA, Whelton A, et al "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982): 594-600
  4. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  5. Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991): 238-9
  6. Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988): 158-63
  7. Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993): 36-9
  8. Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991): 155-6
  9. Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988): 225-8
  10. Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983): 275-83
  11. Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993): 611-5
  12. Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990): 436-8
  13. Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988): 1067-71
View all 13 references
Moderate

Acyclovir (Includes Sitavig) ↔ Dehydration

Moderate Potential Hazard, High plausibility

Applies to: Dehydration

Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus. Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure. Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration. Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration. The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs. The recommended urine output is a minimum of 500 mL per gram of drug infused.

References

  1. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
Moderate

Acyclovir (Includes Sitavig) ↔ Hemodialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Acyclovir is substantially removed by hemodialysis. Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis. Acyclovir should be administered after hemodialysis. Otherwise, an additional dose may be given after each hemodialysis session.

References

  1. Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982): 202-4
  2. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
Moderate

Acyclovir (Includes Sitavig) ↔ Neurotoxicity

Moderate Potential Hazard, Low plausibility

Applies to: Liver Disease, Electrolyte Abnormalities, Hypernatremia, Phosphate Imbalance, Magnesium Imbalance, Asphyxia, CNS Disorder, Hyponatremia, Dehydration, Hypocalcemia, Hypercalcemia, Acidosis, Alkalosis

Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma. Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.

References

  1. Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985): 362-5
  2. Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988): 385-8
  3. Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993): 507-11
  4. Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994): 460-3
  5. Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983): 921-5
  6. Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986): 892
  7. MacDiarmaid-Gordon AR, O'Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992): 280-3
  8. Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993): 36-9
  9. Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988): 158-63
  10. Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990): 300-1
  11. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  12. Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984): 920
View all 12 references

Sitavig (acyclovir) drug Interactions

There are 79 drug interactions with Sitavig (acyclovir)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide